Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies

Antibody Drug Discovery

Volumn , Issue , 2011, Pages 147-220

  Strohl, William R ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85131469670     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781848166295_0005     Document Type: Chapter

References (257)

1. Aalberse R.C., Schuurman J. (2002). IgG4, breaking all the rules. Immunology 105: 9-19.
2. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. (2009). Immunoglobulin IgG4: an odd antibody. Clin Exp Allergy 39: 469-77.
3. Alegre M.L., Peterson L.J., Xu D., Sattar H.A., Jeyarajah D.R., Kowalkowski K., Thistlewaite J.R., Zivin R.A., Jolliffe L., Bluestone J.A. (1994). A non-activating “humanized” anti-CD3 monoclonal antibody retains innunosuppressive properties in vivo. Transplantation 57: 1537-43.
4. Alexion Pharmaceuticals. (2007). Soliris® prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/125166lbl.pdf
5. Allan B., Jiang W., Tang Y., Watkins J.D. (2006). Variant Fc regions. WO 2006/020114 Publ. 2/23/2006.
6. Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D., Roberts G., Pedley B., Adair J.R. (1993). A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30: 105-8.
7. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. (2008a). Recapitulation of IVIG anti-Inflammatory activity with a recombinant IgG Fc. Science 320: 373-6.
8. Anthony R.M., Wermeling F., Karlsson M.C.I., Ravetch J.V. (2008b). Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105: 19571-8.
9. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., Rudd P.M., Sim R.B. (2005). Human serum IgM glycosylation. Identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 280: 29080-7.
10. Arnold J.N., Dwek R.A., Rudd P.M., Sim R.B. (2006). Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 106: 103-10.
11. Arora T., Padaki R., Liu L., Hamburger A.E., Ellison A.R., Stevens S.R., Louie J.S., Kohno T. (2009). Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45: 124-31.
12. Azuma Y., Ishikawa Y., Kawai S., Tsunenari T., Tsunoda H., Igawa T., Iida S.-i., Nanami M., Suzuki M., Irie R.F., Tsuchiya M., Yamada-Okabe H. (2007). Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clin Cancer Res 13: 2745-50.
13. Baerenwaldt A., Nimmerjahn F. (2008). Fc-RIIB-regulating the balance between protective and autoreactive immune responses. Immunol Cell Biol 86: 482-4.
14. Baudino L., Nimmerjahn F., Azeredo da Silveira S., Martinez-Soria E., Saito T., Carroll M., Ravetch J.V., Verbeek J.S., Izui S. (2008a). Differential contribution of three activating IgG Fc receptors (Fc-RI, Fc-RIII, and Fc-RIV) to IgG2a-and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol 180: 1948-53.
15. Baudino L., Nimmerjahn F., Shinohara Y., Furukawa J.-I., Petry F., Verbeek J.S., Nishimura S.-I., Ravetch J.V., Izui S. (2008b). Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 181: 4107-12.
16. Beers S.A., Chan C.H., James S., French R.R., Attfield K.E., Brennan C.M., Ahuja A., Shlomchik M.J., Cragg M.S., Glennie M.J. (2008). Type II (tositumomab) anti-CD20 monoclonal antibody out performs Type I (rituximab-like) reagents in B cell depletion reguardless of complement activation. Blood 112: 4170-7.
17. Beliard R., Waegemans T., Notelet D., Massad L., Dhainaut F., de Romeuf C., Guemas E., Haazen W., Bourel D., Teillaud J.-L., Prost J.-F. (2008). A human anti-D monoclonal antibody selected for enhanced Fc-RIII engagement clears RhD-autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Brit J Haematol 141: 109-19.
18. Bello C., Sotomayor E.M. (2007). Monoclonal antibodies for B cell lymphomas: rituximab and beyond. Hematol Amer Soc Hematol Educ Program 2007: 233-42.
19. Bendele A., Seely J., Richey C., Sennello G., Shopp G. (1998). Short Communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42: 152-7.
20. Beutner U., Lorenz U., Illerti B., Rotti L., Timmermann W., Vollmers H.P., Muller-Hermelink H.K., Thiede A., Ulrichs K. (2008). Neoadjuvant therapy of gastric cancer with the human monoclonal IgM antibody SC-1: Impact on the immune system. Oncol Rep 19: 761-9.
21. Beyer T., Lohse S., Berger S., Peipp M., Valerius T., Dechant M. (2009). Serum-free production and purification of chimeric IgA antibodies. J Immunol Meth 346: 26-37.
22. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., Lamy A., Penault-Llorca F., Frebourg T., Michel P., Sabourin J.-C., Boissiere-Michot F. (2009). Impact of Fc-RIIa-Fc-RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27: 1122-9.
23. Bindon C.I., Hale G., Brüggemann M., Waldman H. (1988). Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168: 127-42.
24. Bindon C.I., Hale G., Waldmann H. (1990). Complement activation by immunoglobulin does not depend solely on C1q binding. Eur J Immunol 20: 277-81.
25. Boel E., Verlaan S., Poppelier M.J., Nomdo J.G., Westerdaal A.C., Van Strijp J.A.G., Logtenberg T. (2000). Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239: 153-66.
26. Bolt S., Routledge E., Lloyd I., Chatenoud L., Pope H., Gorman S.D., Clark M., Waldmann H. (1993). The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23: 403-11.
27. Bonner A., Almogren A., Furtado P.B., Kerr M.A., Perkins S.J. (2009). The nonplanar secretory IgA2 and near planar secretory IgA1 solution structures rationalize their different mucosal immune responses. J Biol Chem 284: 5077-87.
28. Bournazos S., Woof J.M., Hart S.P., Dransfield I. (2009). Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 157: 244-54.
29. Braathen R., Sørensen V., Brandtzaeg P., Sandlie I., Johansen F.-E. (2002). The carboxylterminal domains of IgA and IgM direct isotype-specific polymerization and interaction with the polymeric immunoglobulin receptor. J Biol Chem 277: 42755-62.
30. Brandtzaeg P., Prydz H. (1984). Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 311: 71-3.
31. Bredius R.G.M., Fijen C.A.P., de Haas M., Kuijper E.J., Weening R.S., van de Winkel J.G.J., Out T.A. (1994). Role of neutrophil Fc-RIIa (CD32) and Fc-RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1-and IgG3-opsonized bacteria and erythrocytes. Immunology 83: 624-30.
32. Bruckheimer E.M., Fazenbaker C.A., Gallagher S., Mulgrew K., Furmann S., Coffman K.T., Walsh W., Ready S., Cook K., Damschroder M., Kinch M., Kiener P.A., Woods R., Gao C., Dall’Acqua W., Wu H., Coats S. (2009). Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 11: 509-17.
33. Brüggemann M., Williams G.T., Bindon C.I., Clark M.R., Walker M.R., Jefferis R., Waldmann H., Neuberger M.S. (1987). Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exptl Med 66: 1351-61.
34. Brüggemann M., Teale C., Clark M., Bindon C., Waldmann H. (1989). A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions ?, -1, -2a, -2b, -2c, -, and γ. J Immunol 142: 3145-50.
35. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. (2009). Specificity and affinity of human Fc..receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-25.
36. Cardarelli P.M., Moldovan-Loomis M.-C., Preston B., Black A., Passmore D., Chen T.-H., Chen S., Liu J., Kuhne M.R., Srinivasan M., Assad A., Witte A., Graziano R.F., King D.J. (2009). In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 15: 3376-83.
37. Carter P.J. (2006). Potent antibody therapeutics by design. Nature Rev Immunol 6: 343-57.
38. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bordos P., Colombat P., Watier H. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in igG Fc receptor FcgammaRIIIa gene. Blood 99: 754-8.
39. Cassard L., Cohen-Solal J.F.G., Fournier E.M., Camilleri-Broët S., Spatz A., Chouaïb S., Badoual C., Varin A., Fisson S., Duvillard P., Boix C., Loncar S.M., Sastre-Garau X., Houghton A.N., Avril M.-F., Gresser I., Fridman W.H., Sautès-Fridman C. (2008). Selective expression of inhibitory Fc..receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Internat J Cancer 123: 2832-9.
40. Cerutti A., Rescigno M. (2008). The biology of intestinal immunoglobulin A responses. Immunity 28: 740-50.
41. Chan L.A., Lyczak J.B., Zhang K., Morrison S.L., Saxon A. (2000). The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex. Mol Immunol 37: 241-52.
42. Chang T.W., Shiung Y.Y. (2006). Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 117: 1203-12.
43. Chapman K., Pullen N., Graham M., Ragan I. (2007). Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Rev Drug Discovery 6: 120-6.
44. Chaturvedi A., Siddiqui Z., Bayiroglu F., Rao K.V.S. (2002). A GPI-linked isoform of the IgD receptor regulates resting B cell activation. Nature Immunol 3: 951-7.
45. Cheung N.K., Sowers R., Vickers A.J., Cheung I.Y., Kushner B.H., Gorlick R. (2006). FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colonystimulating factor. J Clin Oncol 24: 2885-90.
46. Chong K.T., Ho W.F., Koo S.H., Thompson P., Lee E.J.D. (2006). Distribution of the Fc-RIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore. Brit J Clin Pharmacol 63: 328-32.
47. Chowdhury P.S., Wu H. (2005). Tailor-made antibody therapeutics. Methods 36: 11-24.
48. Chu S.Y., Vostiar I., Kaki S., Moore G.L., Lazar G.A., Pong E., Joyce P.F., Szymkowski D.E., Desjarlais J.R. (2008). Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc-RIIb with Fc-engineered antibodies. Molec Immunol 45: 3926-33.
49. Clark M. (1997). Ig effector mechanisms. Chem Immunol 65: 88-110.
50. Cole M.S., Stellrecht K.E., Shi J.D., Homola M., Hsu D.-H., Anasetti C., Vasquez M., Tso J.Y. (1999). HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68: 563-71.
51. Collins C.W.L., Tsui F.W.L., Shulman M.J. (2002). Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol 32: 1802-10.
52. Coxon A., Cullere X., Knight S., Sethi S., Wakelin M.W., Stavrakis G., Luscinskas F.W., Mayadas T.N. (2001). Fc-RIII mediates neutrophil recruitment to immune complexes: A mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity 14: 693-704.
53. Dall’Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., Wu H., Kiener P.A., Langermann S. (2002). Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169: 5171-80.
54. Dall’Acqua W.F., Kiener P.A., Wu H. (2006). Properties of human IgG1 engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281: 23514-24.
55. Datta-Mannan A., Wichter D.R., Tang Y., Watkins J., Jiang W., Wroblewski V.J. (2007a). Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab Disposition 35: 86-94.
56. Datta-Mannan A., Wichter D.R., Tang Y., Watkins J., Wroblewski V.J. (2007b). Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282: 1709-17.
57. Davis P.M., Abraham R., Xu L., Nadler S.G., Suchard S.J. (2007). Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 34: 2204-10.
58. Dechant M., Beyer T., Schneider-Merck T., Weisner W., Peipp M., van de Winkel J.G.J., Valerius T. (2007). Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 179: 2936-43.
59. De la Cruz Edmunds M.C., Tellers M., Chan C., Salmon P., Robinson D.K., Markussen J. (2006). Development of transfection and high-producer screening protocols for the CHOK1SV cell system. Mol Biotechnol 34: 179-90.
60. der Balian G.P., Slack J., Clevinger B.L., Hervi-Bazin U., Davie J.M. (1980). Subclass restriction of murine antibodies. III. Antigens that stimulate IgG3 in mice stimulate IgG2 in rats. J Exp Med 152: 209-18.
61. Desjarlais J.R., Lazar G.A., Zhukovsky E.A., Chu S.Y. (2007). Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discovery Today 12: 898-910.
62. Díaz de Ståhl T., Dahlström J., Carroll M.C., Heyman B. (2003). A role for complement in feedback enhancement of antibody responses by IgG3. J Exp Med 197: 1183-90.
63. Dillman S.L., Strelkauskas A.J., Sut H.R., Boakle R.J. (1995). Activation of human complement by totally human monoclonal antibodies. Molec Immunol 32: 957-64.
64. Dillon T.M., Ricci M.S., Vezina C., Flynn G.C., Liu Y.D., Rehder D.S., Plant M., Henkle B., Li Y., Deechongkit S., Varnum B., Wypych J., Balland A., Bondarenko P.V. (2008). Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 283: 16206-15.
65. Dimitrov D.S., Marks, J.D. (2008). Therapeutic antibodies: current state and future trends-is a paradigm change coming soon? Methods Mol Biol 525: 1-27.
66. Ding J.W., Zhou T., Zeng H., Ma L., Sjef Verbeek J., Yin D., Shen J., Chong A.S. (2008). Hyperacute rejection by anti-gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-..receptors. J Immunol 180: 261-8.
67. Dong X., Storkus W.J., Salter R.D. (1999). Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 163: 5427-34.
68. Doyle A.G., Woolven B.P., Tomlinson I.M., Lee J.A., Jennings P.A. (2007). Domain antibody construct. WO 2007/087673 A1.
69. Duncan A.R., Winter G. (1988). The binding site for C1q on IgG. Nature 332: 738-40.
70. Ernst L.K., Metes D., Herberman R.B., Morel P.A. (2002). Allelic polymorphisms in the Fcgamma RIIc gene can influence its function on normal human natural killer cells. J Mol Med 80: 248-57.
71. Ferrante A., Beard L.J., Feldman R.G. (1990). IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J 9: S16-24.
72. Feige M.J., Nath S., Catharino S.R., Weinfurtner D., Steinbacher S., Buchner J. (2009). Structure of the murine unglycosylated IgG1 Fc fragment. J Mol Biol 391: 599-608.
73. Foulkes R. (2002). Preclinical safety evaluation of monoclonal antibodies. Toxicology 174: 21-6.
74. Gagnon P., Hensel F., Richieri R. (2008). Purification of IgM monoclonal antibodies. BioPharm Internat 26 March suppl: 26-35.
75. García-García E., Nieto-Castañeda G., Ruiz-Saldaña M., Mora N., Rosales C. (2009). Fc-RIIA and Fc-RIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. J Immunol 182: 4547-56.
76. Gasque P. (2004). Complement: a unique innate immune sensor for danger signals. Molec Immunol 41: 1089-98.
77. Ghetie V., Ward E.S. (2000). Multiple roles for the major histocompatibility complex Class I-related receptor FcRn. Annu Rev Immunol 18: 739-66.
78. Ghirlando R., Lund J., Goodall M., Jefferis R. (1999). Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett 68: 47-52.
79. Ghumra A., Shi J., Mcintosh R.S., Rasmussen I.B., Braathen R., Johansen F.E., Sandlie I., Mongini P.K., Areschoug T., Lindahl G., Lewis M.J., Woof J.M., Pleass R.J. (2009). Structural requirements for the interaction of human IgM and IgA with the human Fc γ/receptor. Eur J Immunol 39: 1147-56.
80. Giorgini A., Brown H.J., Lock H.R., Nimmerjahn F., Ravetch J.V., Verbeek J.S., Sacks S.H., Robson M.G. (2008). Fc-RIII and Fc-RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol 181: 8745-52.
81. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. (2007). Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-37.
82. Gounni A.S. (2006). The high-affinity IgE receptor (Fc-RI): a critical regulator of airway smooth muscle cells? Am J Physiol Lung Cell Mol Physiol 291: L312-21.
83. Greenspan N.S., Cooper L.J.N. (1992). Intermolecular cooperativity: a clue to why mice have IgG3? Immunol Today 13: 164-8.
84. Guo A., Han M., Martinez T., Ketchem R.R., Novick S., Jochheim C., Balland A. (2008). Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype. Electrophoresis 29: 2550-6.
85. Hamaguchi Y., Xiu Y., Komura K., Nimmerjahn F., Tedder T.F. (2006). Antibody isotypespecific engagement of Fc..receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203: 743-53.
86. Hart S.P., Alexander K.M., Dransfield I. (2004). Immune complexes bind preferentially to Fc-RIIA (CD32) on apoptotic neutrophils, leading to augmented phagocytosis by macrophages and release of proinflammatory cytokines. J Immunol 172: 1882-7.
87. Harwood N.E., McDonnell, J.M. (2007). The intrinsic flexibility of IgE and its role in binding Fc-RI. Biomedicine Pharmacotherapy 61: 61-7.
88. Hayden-Ledbetter M.S., Cerveny C.G., Espling E., Brady W.A., Grosmaire L.S., Tan P., Bader R., Slater S., Nilsson C.A., Barone D.S., Simon A., Bradley C., Thompson P.A., Wahl A.F., Ledbetter J.A. (2009). CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 15: 2739-46.
89. Hazenbos W.L., Heijnen I.A., Meyer D., Hofhuis F.M., Renardel de Lavalette C.R., Schmidt R.E., Capel P.J., van de Winkel J.G., Gessner J.E., van den Berg T.K., Verbeek J.S. (1998). Murine IgG1 complexes trigger immune effector functions predominantly via Fc-RIII (CD16). J Immunol 161: 3026-32.
90. Herr A.B., White C.L., Milburn C., Wu C., Bjorkman P.J. (2003). Bivalent binding of IgA1 to FcγRI suggests a mechanism for cytokine activation of IgA phagocytosis. J Mol Biol 327: 645-57.
91. Hinton P.R., Xiong J.M., Johlfs M.J., Tang M.T., Keller S., Tsurushita N. (2006). An engineered human IgG1 antibody with longer serum half-life. J Immunol 176: 346-56.
92. Hirano M., Davis R.S., Fine W.D., Nakamura S., Shimizu K., Yagi H., Kato K., Stephan R.P., Cooper M.D. (2007). IgEb immune complexes activate macrophages through Fc-RIV binding. Nature Immunol 8: 762-71.
93. Hoon D.S., Wang Y., Sze L., Kanda H., Watanabe Y., Morrison S.L., Morton D.L., Irie R.F. (1993). Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res 53: 5244-50.
94. Holland M., Hewins P., Goodal M., Adu D., Jefferis R., Savage C.O. (2004). Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener’s granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol 138: 183-92.
95. Horton H.M., Bernett M.J., Pong E., Piepp M., Karki S., Chu S.Y., Richards J.O., Vostiar I., Joyce P.F., Repp R., Desjarlais J.R., Zhukovsky E.A. (2008). Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68: 8049-57.
96. Hsu E., Pulham N., Rumfelt L.L., Flajnik M.F. (2006). The plasticity of immunoglobulin gene systems in evolution. Immunol Rev 210: 8-26.
97. Hughey C.T., Brewer J.W., Colosia A.D., Rosse W.F., Corley R.B. (1998). Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol 161: 4091-7.
98. Hutchins J.T., Kull F.C., Jr., Bynum J., Knick V.C., Thurmond L.M., Ray P. (1995). Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with gamma 4 variant of Campath-1H. Proc Natl Acad Sci USA 92: 11980-4.
99. Idusogie E.E., Presta L.G., Gazzano-Santoro H., Totpal K., Wong P.Y., Ultsch M., Meng Y.G., Mulkerrin, M.G. (2000). Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164: 4178-84.
100. Iida S., Kuni-Kamochi R., Mori K., Misaka H., Inoue M., Okazaki A., Shitara K., Satoh M. (2009). Two mechanisms of enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 9: 58, 1-12.
101. Inoue Y., Kaifu T., Sugahara-Tobinai A., Nakamura A., Miyazaki J.-I., Takai T. (2007). Activating Fc..receptors participate in the development of autoimmune diseases in NOD mice. J Immunol 179: 764-74.
102. Ip W.K., Takahashi K., Ezekowitz R.A., Stuart L.M. (2009). Mannose binding lectin and innate immunity. Immunol Rev 230: 9-21.
103. Irie R.F., Ollila D.W., O’Day S., Morton D.L. (2004). Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 53: 110-7.
104. Isaacs J.D., Wing M.G., Greenwood J.D., Hazleman B.L., Hale G., Waldman H. (1996). A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 106: 427-33.
105. Ishizaka K., Ishizaka T. (1970). Biological function of -E antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 6: 25-42.
106. Ito A., Ishida T., Yano H., Inagaki A., Suzuki S., Sato F., Takino H., Mori F., Ri M., Kusumoto S., Komatsu H., Iida S., Inagaki H., Ueda R. (2009). Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2R-null mouse model. Cancer Immunol Immunother 58: 1195-206.
107. Jakus Z., Németh T., Verbeek J.S., Mócsai A. (2008). Critical but overlapping role of Fc-RIII and Fc-RIV in activation of murine neutrophils by immobilized immune complexes. J Immunol 180: 618-29.
108. Jansen W.T.M., Breukels M.A., Snippe H., Sanders L.A.M., Verheul A.F.M., Rijkers G.T. (1999). Fc..receptor polymorphisms determine the magnitude of in vitro phagocytosis of Streptococcus pneumoniae mediated by pneumococcal conjugate sera. J Infectious Dis 180: 888-91.
109. Jefferis R. (2007). Antibody therapeutics: isotype and glycoform selection. Expert Opin Ther 7: 1401-13.
110. Jefferis R. (2009a). Glycosylation as a strategy to improve antibody-based therapeutics. Nature Rev Drug Disc 8: 226-34.
111. Jefferis R. (2009b). Recombinant antibody therapeutics: the impact of glycosylation on mechanism of action. Trends Pharmacol Sci 30: 356-62.
112. Johansen F.E., Braathen R., Brandtzaeg P. (2000). Role of J chain in secretory immunoglobulin formation. Scand J Immunol 52: 240-8.
113. Kaetzel C.S. (2005). The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 206: 83-99.
114. Kamisawa T., Okamoto A. (2006). Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 41: 613-25.
115. Kaneko Y., Nimmerjahn F., Ravetch J.V. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-3.
116. Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Karaoglu Hanzatian D., Salfeld J., Sasso E.H. (2009). Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clinical Immunology 131: 308-16.
117. Kazeeva T.N., Shevelev A.B. (2009). IgA-specific proteins of pathogenic bacteria. Biochemistry (Moscow) 74: 12-21.
118. Kilmon M.A., Shelburne A.E., Chan-Li Y., Holmes K.L. Conrad D.H. (2004). CD23 trimers are preassociated on the cell surface even in the absence of its ligand, IgE. J Immunol 172: 1065-73.
119. Kim J.K., Firan M., Radu C.G., Kim C.-H., Ghetie V., Ward E.S. (1999). Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol 29: 2819-25.
120. Kishore U., Reid K.B.M. (2000). C1q: structure, function, and receptors. Immunopharmacology 49: 159-70.
121. Knight K.L., Winstead C.R. (1997). Generation of antibody diversity in rabbits. Curr Opin Immunol 9: 228-32.
122. Köhler G., Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-7.
123. Kumagai Y., Fujita T., Ozaki M., Sahashi K., Ohkura M., Ohtsu T., Arai Y., Sonehara Y., Nichol J.L. (2007). Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: A randomized, placebo-controlled study. J Clin Pharmacol 47: 1489-97.
124. Labrijn A.F., Aalberse R.C., Schuurman J. (2008). When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20: 479-85.
125. Labrijn A.F., Buijsse A.O., van den Bremer E.T.J., Verwilligen A.Y.W., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G.J., Parren P.W.H.I. (2009). Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnol 27: 767-71.
126. Lai Z., Kimmela R., Petersen S., Thomas S., Pier G., Bezabeh B., Luod R., Schreiber J.R. (2005). Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23: 3264-71.
127. Larrick J.W., Yu L., Naftzger C., Jaiswal S., Wycoff K. (2001). Production of secretory IgA antibodies in plants. Biomolec Eng 18: 87-94.
128. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Veilmetter J., Carmichael D.F., Hayes R.J., Dahiyat B.I. (2006). Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005-10.
129. Li H., Sethuraman N., Stadheim T.A., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B.K., Cook W.J., Cukan M., Houston-Cummings N.R., Davidson R., Gong B., Hamilton S.R., Hoopes J.P., Jiang Y., Kim N., Mansfield R., Nett J.H., Rios S., Strawbridge R., Wildt S., Gerngross T.U. (2006a). Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnol 24: 210-15.
130. Li J., Davis J., Bracht M., Carton J., Armstrong J., Gao W., Scallon B., Fung R., Emmel E., Zimmerman M., Griswold D.E., Li L. (2006b). Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Internat Immunopharmacol 6: 880-91.
131. Li P., Jiang N., Nagarajan S., Wohlhueter R., Selvaraj P., Zhu C. (2007). Affinity and kinetic analysis of Fcgamma receptor IIIa (CD16a) binding to IgG ligands. J Biol Chem 282: 6210-21.
132. Lin Q., Xiu Y., Jiang Y., Tsurui H., Nakamura K., Kodera S., Ohtsuji M., Ohtsuji N., Shiroiwa W., Tsukamoto K., Amano H., Amano E., Kinoshita K., Sudo K., Nishimura H., Izui S., Shirai T., Hirose S. (2006). Genetic dissection of the effects of stimulatory and inhibitory IgG Fc receptors on murine lupus. J Immunol 177: 1646-54.
133. Lin X., Ding J., Zhu L., Shi S., Jiang L., Zhao M., Zhang H. (2009). Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 24: 3372-5.
134. Longstaff C., Whitton C.M., Stebbings R., Gray E. (2009). How do we assure the quality of biological medicines? Drug Discovery Today 14: 50-5.
135. Lucisano-Valim Y.M., Lachmann P.J. (1991). The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: A systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Inmunol 84: 1-8.
136. Ma J.K., Hikmat B.Y., Wycoff K., Vine N.D., Chargelegue D., Yu L., Hein M.B., Lehner T. (1998). Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nature Med 4: 601-6.
137. Maenaka K., van der Merwe P.A., Stuart D.I., Jones E.Y., Sondermann P. (2001). The human pow affinity Fc..receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem 276: 44898-904.
138. Mancardi D.A., Iannascoli B., Hoos S., England P., Daeron M., Bruhns P. (2008). Fc-RIV is a mouse IgE receptor that resembles macrophage Fc-RI in humans and promotes IgEinduced lung inflammation. J Clin Invest 118: 3738-50.
139. McEarchern J.A., Oflazoglu E., Francisco L., McDonagh C.F., Gordon K.A., Stone I., Klussman K., Turcott E., van Rooijen N., Carter P., Grewal I.S., Wahl A.F., Law C.-L. (2007). Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109: 1185-92.
140. McLay J., Leonard E., Petersen S., Shapiro D., Greenspan N.S., Schreiber J.R. (2002). -3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J Immunol 168: 3437-43.
141. Michaelsen T.E., Aase A., Norderhaug L., Sandlie I. (1992). Antibody dependent cellmediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol Immunol 29: 319-26.
142. Minard-Colin V., Xiu Y., Poe J.C., Horikawa M., Magro C.M., Hamaguchi Y., Haas K.M., Tedder T.F. (2008). Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc-RI, Fc-RIII, and Fc-RIV. Blood 112: 1205-13.
143. Mitoma H., Horiuchi T., Tsukamoto H., Tamimoto Y., Kimoto Y., Uchino A., Kentaro T., Harashima S.-i., Hatta N., Harada M. (2008). Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alphaexpressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58: 1248-57.
144. Monteiro R.C., van deWinkel J.G.J. (2003). IgA Fc receptors. Annu Rev Immunol 21: 177-204.
145. Morrison S.L., Chintalacharuvu K.R. (2001). Secretory immunoglobulin produced by single cells and methods for making and using same. US Patent 6, 300, 104 B1.
146. Mota G., Manciulea M., Cosma E., Popescu I., Hirt M., Jensen-Jarolim E., Calugaru A., Galatiuc C., Regalia T., Tamandl D., Spittler A., Boltz-Nitulescu G. (2003). Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol 33: 2197-205.
147. Mueller J.P., Giannoni M.A., Hartman S.L., Elliott E.A., Squinto S.P., Matis L.A., Evans M.J. (1997). Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Molec Immunol 34: 441-52.
148. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., Neri T.M., Ardizzoni A. (2008). Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-96.
149. Nakamura A., Akiyama K., Takai T. (2005). Fc receptor targeting in the treatment of allergy, autoimmune diseases and cancer. Expert Opin Therap Targets 9: 169-90.
150. Natsume A., In M., Takamura H., Nakagawa T., Shimizu Y., Kitajima K., Wakitani M., Ohta S., Satoh M., Shitara K., Niwa R. (2008). Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 68: 3863-72.
151. Neuberger M.S., Williams G.T., Fox R.O. (1984). Recombinant antibodies possessing novel effector functions. Nature 312: 604-8.
152. Nielsen L.K., Hefsgaard Green T., Norderhaug L., Sandlie I., Hanefeld Dziegiel M. (2007). Functional in vitro studies of recombinant human immunoglobulin G and immunoglobulin A anti-D. Transfusion 47: 306-15.
153. Nimmerjahn F., Bruhns P., Horiuchi K., Ravetch J.V. (2005). Fc-RIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51.
154. Nimmerjahn F., Ravetch J.V. (2006). Fc..Receptors: Old friends review and new family members. Immunity 24: 19-28.
155. Nimmerjahn F., Ravetch J.V. (2007). The anti-inflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204: 11-5.
156. Nimmerjahn F., Ravetch J.V. (2008). Fc..receptors as regulators of immune responses. Nature Rev Immunol 8: 34-47.
157. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., Yodoi H., Nakamura K., Shitara K. (2004). Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRllla functional polymorphism. Clin Cancer Res 10: 6248-55.
158. Niwa R., Natsume A., Uehara A., Wakitani M., Iida S., Uchida K., Satoh M., Shitara K. (2005). IgG subclass-independent improvement of antibody dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Meth 306: 151-60.
159. Norderhaug I.N., Johansen F.-E., Krajci P., Bradzaeg P. (1999). Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction. Eur J Immunol 29: 3401-9.
160. Nozawa S., Aoki D., Tsukazaki K., Susumu N., Sakayori M., Suzuki N., Suzuki A., Wakita R., Mukai M., Egami Y., Kojima-Aikawa K., Ishida I., Belot F., Hindsgaul O., Fukuda M., Fukuda M.N. (2004). A humanized monoclonal antibody with therapeutic potential against Müllerian duct-related carcinomas. Clin Cancer Res 10: 7071-8.
161. Oflazoglu E., Stone I.J., Gordon K.A., Greal I.S., van Rooijen N., Law C.-L., Gerber H.-P. (2007). Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110: 4370-2.
162. Oflazoglu E., Stone I.J., Brown L., Gordon K.A., van Rooijen N., Jonas M., Law C.-L., Grewal I.S., Gerber H.-P. (2009). Macrophages and Fc-receptor interactions contribute to the antitumor activities of the anti-CD40 antibody SGN-40. Brit J Cancer 100: 113-7.
163. Oganesyan V., Gao C., Shirinian L., Wu H., Dall’Acqua W.F. (2008). Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Cryst D64: 700-4.
164. Ohta Y., Flajnik M. (2006). IgD, like IgM, is a primordial immunoglobulin class perpetuated in most jawed vertebrates. Proc Natl Acad Sci USA 103: 10723-8.
165. Pack T.D. (2000). Purification of IgA. Curr Protocols Immunol 2: 2.10B.1-2.10B.7
166. Pancook J.D., Beuerlein G., Pecht G., Tang Y., Nie Y., Wu H., Huse W.D., Watkins J.D. (2001). In vitro affinity maturation of human IgM antibodies reactive with tumorassociated antigens. Hybridoma Hybridomics 20: 383-96.
167. Penichet M.L., Morrison S.L. (2001). Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248: 91-101.
168. Petkova S.B., Akilesh S., Sproule T.J., Christianson G.J., Al Khabbaz H., Brown A.C., Presta L.G., Meng Y.G., Roopenian D.C. (2006). Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Internat Immunol 18: 1759-69.
169. Platonov A.E., Shipulin G.A., Vershinina I.V., Dankert J., van de Winkel J.G.J., Kuijper E.J. (1998). Association of human Fc-RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 27: 746-50.
170. Presta, L.G. (2006). Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58: 640-56.
171. Presta, L.G. (2008). Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20: 460-70.
172. Pricop L., Rabinowich H., Morel P.A., Sulica A., Whiteside T.L., Herberman R.B. (1993). Characterization of the Fc receptor on human natural killer cells. Interaction with its physiological ligand, human normal IgM, specificity of binding, and functional effects. J Immunol 151: 3018-29.
173. Preud’homme J.-L., Petit I., Barra A., Morel F., Lecron J.-C., Lelièvre E. (2000). Structural and functional properties of membrane and secreted IgD. Molec Immunol 37: 871-87.
174. Raju T.S. (2008). Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20: 471-6.
175. Ravetch J.V., Bolland S. (2001). IgG Fc receptors. Annu Rev Immunol 19: 275-90.
176. Reddy M.P., Kinney C.A.S., Chaikin M.A., Payne A., Fishman-Lobell J., Tsui P., Dal Monte P.R., Doyle M.L., Brigham-Burke M.R., Anderson D., Reff M., Newman R., Hanna N., Sweet R.W., Truneh A. (2000). Elimination of Fc receptor-dependent effector functions of a modified IgG4 mAb to human CD4. J Immunol 164: 1925-33.
177. Reichert J.M., Dewitz M.C. (2004). Anti-infective monoclonal antibodies: perils and promise of development. Nature Rev Drug Disc 5: 191-5.
178. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. (2008). Optimization of antibody binding to Fc-RIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Therap 7: 2517-27.
179. Ricklin D., Lambris J.D. (2007). Complement-targeted therapeutics. Nature Biotechnol 25: 1265-75.
180. Robak T. (2009). GA-101. A third-generation, humanized and glycol-engineered anti-CD20 mAb for the treatment of B cell lymphoid malignancies. Curr Opin Investig Drugs 10: 588-96.
181. Rogers K.A., Scinicariello F., Attanasio R. (2006). IgG Fc receptor III homologues in nonhuman primate species: Genetic characterization and ligand interactions. J Immunol 177: 3848-56.
182. Rother R.P., Rollins S.A., Mojcik C.J., Brodsky R.A., Bell L. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnol 25: 1256-64.
183. Saeki T., Nishi S., Ito T., Yamazaki H., Miyamura S., Emura I., Imai N., Ueno M., Saito A., Gejyo F. (2007). Renal lesions in IgG4-related systemic disease. Intern Med. 46: 1365-71.
184. Salfeld J.G. (2007). Isotype selection in antibody engineering. Nature Biotechnol 25: 1369-72.
185. Samuelsson A., Towers T.L., Ravetch J.V. (2001). Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-6.
186. Samuelsson M., Jendholm J., Amisten S., Morrison S.L., Forsgren A., Riesbeck K. (2006). The IgD CH1 region contains the binding site for the human respiratory pathogen Moraxella catarrhalis IgD binding protein MID. Eur J Immunol 36: 2525-34.
187. Sanders L.A.M., Feldman R.G., Voorhorst-Ogink M.D., de Haas M., Rijkers G.T., Capel P.J., Zegers B.J., van de Winkel J.G. (1995). Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 63: 73-81.
188. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D. (2008). Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA 105: 20167-72.
189. Scallon B., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. 1995. Chimeric anti-TNF-γ monoclonal antibody cA2 binds recombinant transmembrane TNF-γ and activates immune effector functions. Cytokine 7: 251-9.
190. Scallon B., McCarthy S., Radewonuk J., Cai A., Naso M., Raju T.S., Capocasale R. (2007a). Quantitative in vivo comparisons of the Fc..receptor-dependent agonist activities of different fucosylation variants of an immunoglobulin G antibody. Internat Immunopharmacol 7: 761-72.
191. Scallon B.J., Tam S.H., McCarthy S.G., Cai A.N., Raju T.S. (2007b). Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Molec Immunol 44: 1524-34.
192. Schumaker V.N., Calcott M.A., Spiegelberg H.L., Muller-Eberhard H.J. (1976). Ultracentrifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 16: 5175-81.
193. Schuurman J., Van Ree R., Perdok G.J., Van Doorn H.R., Tan K.Y., Aalberse R.C. (1999). Normal human immunoglobulin G4 is bispecific: it has two different antigencombining sites. Immunology 97: 693-8.
194. Scinicariello F., Engleman C.N., Jayashankar L., McClure H.M. Attanasio R. (2004). Rhesus macaque antibody molecules: sequence and heterogeneity of γ and. .constant regions. Immunology 111: 66-74.
195. Seino J., Eveleigh P., Warnaar S., Van Haarlem L.J.M., Van Es L.A., Daha M.R. (1993). Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies. Clin Exp Immunol 94: 291-6.
196. Senior B.W., Woof JM. (2005). Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases. Infect Immun 73: 1515-22.
197. Sethuraman N., Stadheim T.A. (2006). Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17: 341-6.
198. Shearer M.H., Dark R.D., Chodosh J., Kennedy R.C. (1999). Comparison and characterization of Iimunoglobulin G subclasses among primate species. Clin Diagnost Labor Immunol 6: 953-8.
199. Shibata-Koyama M., Iida S., Misaka H., Mori K., Yano K., Shitara K., Satoh M. (2009). Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for Fc-RIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 37: 309-21.
200. Shields R.L., Namenuk A.K., Hog K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., Fox J.A., Presta L.G. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276: 6591-604.
201. Shields R.L., Lai J., Keck R., O’Connell L.Y., Hong K., Meng Y.G., Weikert S.H., Presta L.G. (2002). Lack of fructose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-40.
202. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., Shitara K. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharide shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem 278: 3466-73.
203. Slack J.H. (1987). Strain-dependent IgG subclass response patterns. J Immunol 139: 3734-8.
204. Sontheimer R.D., Racila E., Racila D.M. (2005). C1q: Its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J Invest Dermatol 125: 14-23.
205. Sørensen V., Sundvold V., Michaelsen T.E., Sandlie I. (1999). Polymerization of IgA and IgM: Roles of Cys309/Cys414 and the secretory tailpiece. J Immunol 162: 3448-55.
206. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., Huang L., Johnson S., Bonvini E., Koenig S. (2007). Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fc..receptors. Cancer Res 67: 8882-90.
207. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry J., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., Poole S. (2007). “Cytokine storm” in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179: 3325-31.
208. Steplewski Z., Sun L.K., Shearman C.W., Ghrayeb J., Daddona P., Koprowski H. (1988). Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85: 4852-6.
209. Stockmeyer B., Dechant M., van Egmond M., Tutt A.L., Sundarapandiyan K., Graziano R.F., Repp R., Kalden J.R., Gramatzki M., Glennie M.J., van de Winkel J.G.J., Valerius T. (2000). Triggering Fc γ-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 165: 5954-61.
210. Stoger E., Sack M., Fischer R., Christou P. (2002). Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol 13: 161-6.
211. Strohl W.R. (2010). Non-immunostimulatory antibody and compositions containing the same. US 7, 700, 009, Issued 4/20/2010.
212. Strohl W.R. (2009a). Therapeutic Monoclonal Antibodies-Past, Present, and Future. In Z. An, (ed.), Therapeutic Monoclonal Antibodies-From Bench to Clinic, pp. 4-50. John Wiley & Sons, New York.
213. Strohl W.R. (2009b). Optimization of Fc-Mediated Effector Functions of Monoclonal Antibodies. Curr Opin Biotechnol 20: 685-91.
214. Sun Z., Almogren A., Furtado P.B., Chowdhury B., Kerr M.A., Perkins S.J. (2005). Semiextended solution structure of human myeloma immunoglobulin D determined by constrained X-ray scattering. J Mol Biol 353: 155-73.
215. Swann P.G., Tolnay M., Mutukkumar S., Shapiro M.A., Rellahan B.L., Clouse K.A. (2008). Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 20: 493-9.
216. Tabrizi M.A., Roskos L.K. (2007). Preclinical and clinical safety of monoclonal antibodies. Drug Discovery Today 12: 540-7.
217. Takai T. (2002). Roles of Fc receptors in autoimmunity. Nature Rev Immunol 2: 580-92.
218. Tang Y., Lou J., Alpaugh R.K., Robinson M.K., Marks J.D., Weiner L.M. (2007). Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179: 2816-23.
219. Tao M.-H., Morrison S.L. (1989). Studies of aglycosylated chimeric mouse-human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region. J Immunol 143: 2595-601.
220. Taylor A.I., Gould H.J., Sutton B.J., Calvert R.A. (2008). Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure. J Biol Chem 283: 16384-90.
221. Tchoudakova A., Hensel F., Murillo A., Eng B., Foley M., Smith L., Schoenen F., Hildebrand A., Kelter A.R., Ilag L.L., Vollmers H.P., Brandlein S., McIninch J., Chon J., Lee G., Cacciuttolo M. (2009). High level expression of functional human IgMs in human PER.C6® cells. mAbs 1: 163-71.
222. Thommesen J.E., Michaelsen T.E., Løset G.A., Sandlie I., Brekke O.H. (2000). Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation. Molec Immunol 37: 995-1004.
223. Thurber G.M., Wittrup K.D. (2008). Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res 68: 3334-41.
224. Umana P., Jean-Mairet J., Moudry R., Amstutz H., Bailey J.E. (1999). Engineered glycoforms of an anti-neuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol 17: 176-80.
225. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. (2001). Complement activation plays a key role in the side-effects of rituximab treatment. Brit J Haematol 115: 807-11.
226. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G.J., Aalberse R.C., Parren P.W.H.I. (2007). Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-7.
227. van der Zee J.S., Van Swieten P., Aalberse R.C. (1986). Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 137: 3566-71.
228. van Schie R.C.A.A., Wilson M.E. (2000). Evaluation of human Fc-RIIA (CD32) and Fc-RIIIB (CD16) polymorphisms in Caucasians and African-Americans using salivary DNA. Clin Diagn Lab Immunol 7: 676-81.
229. van Sorge N.M., van der Pol W.L., van de Winkel J.G.J. (2003). Fc-R polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61: 189-202.
230. Veri M.-C., Gorlatov S., Li H., Burke S., Johnson S., Stavenhagen J., Stein K.E., Bonvini E., Koenig S. (2007). Monoclonal antibodies capable of discriminating the human inhibitory Fc--receptor IIB (CD32B) from the activating Fc--receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121: 392-404.
231. Vernersson M., Aveskogh M., Hellman L. (2004). Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages. Dev Comp Immunol 28: 61-75.
232. Vollmers H.P., Brändlein S. (2002). Nature’s best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Human Antibodies 11: 131-42.
233. Vollmers H.P., Brändlein S. (2006). Natural IgM antibodies: The orphaned molecules in immune surveillance. Adv Drug Delivery Rev 58: 755-65.
234. Walker M.R., Lund J., Thompson K.M., Jefferis R. (1989). Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc-RI and/or Fc-RII receptors. Biochem J 259: 347-53.
235. Ward E.S. (2006). Immunoglobulin molecules with improved characteristics. WO 2006/130834.
236. Warrington A.E., Bieber A.J., Ciric B., Pease L.R., Van Keulen V., Rodriguez M. (2007). A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 85: 967-76.
237. Watkins J.D., Allan B. (2004). Fc region variants. WO 2004/074455 A2. Publ 9/2/2004.
238. Weng W.K., Levy R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-7.
239. Wines B.D., Hogarth P.M. (2006). IgA receptors in health and disease. Tissue Antigens 68: 103-14.
240. Wing M.G., Moreau T., Greenwood J., Smith R.M., Hale G., Isaacs J., Waldmann H., Lachmann P.J., Compston A. (1996). Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98: 2819-26.
241. Woof J.M., Burton D.R. (2004). Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Rev Immunol 4: 89-99.
242. Woof J.M., Kerr M.A. (2006). The function of immunoglobulin A in immunity. J Pathol 208: 270-82.
243. Wu B., Joshi A., Ren S., Ng C. (2006). The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab. J Pharm Sci 95: 1258-68.
244. Wycoff K.L. (2004). Secretory IgA Antibodies from Plants. Curr Pharmaceut Design 10: 1381-6128.
245. Wypych J., Li M., Guo A., Zhang Z., Martinez T., Allen M.J., Fodor S., Kelner D.N., Flynn G.C., Liu Y.D., Bondarenko P.V., Speed Ricci M., Dillon T.M., Balland A. (2008). Human IgG2 antibodies display disulfide mediated structural isoforms. J Biol Chem 283: 16194-205.
246. Xu H., Geddes R., Roberts-Thompson P.J. (1994). Low molecular weight IgM and CD5 B lymphocytes in rheumatoid arthritis. Annals Rheum Dis 53: 383-90.
247. Xu D., Alegre M.L., Varga S.S., Rothermel A.L., Collins A.M., Pulito V.L., Hanna L.S., Dolan K.P., Parren P.W., Bluestone J.A., Jolliffe L.K., Zivin R.A. (2000). In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 200: 16-26.
248. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., Satoh M. (2004). Establishment of FUT8 knockout Chinese hamster ovary cells; an ideal host cell line for producing completely defucosylated antibodies with enhanced antibodydependent cellular cytotoxicity. Biotechnol Bioeng 87: 614-22.
249. Yee A.M.F., Phan H.M., Zuniga R., Salmon J.E., Musher D.M. (2000). Association between Fc-RIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 30: 25-8.
250. Yeung Y.A., Leabman M.K., Marvin J.S., Qiu J., Adams C.W., Lien S., Starovasnik M.A., Lowman H.B. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J Immunol 182: 7663-71.
251. Yokota T., Milenic D.E., Whitlow M., Schlom J. (1992). Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-8.
252. Yoo E.M., Wims L.A., Chan L.A., Morrison S.L. (2003). Human IgG2 can form covalent dimers. J Immunol 170: 3134-8.
253. Zalevsky J., Leung I.W.L., Karki S., Chu S.Y., Zhukovsky E.A., Desjarlais J.R., Carmichael D.F., Lawrence C.E. (2009). The impact of Fc engineering on an anti-CD19 antibody: increased Fc..receptor affinity enhances B cell clearing in nonhuman primates. Blood 113: 3735-43.
254. Zeidler R., Reisbach G., Wollenberg B., Lang S., Chaubel S., Schmitt B., Lindhofer H. (1999). Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163: 1246-52.
255. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., Chang H.-M., Borucka E., Lurje G., Sherrod A.E., Iqbal S., Groshen S., Lenz H.-J. (2007). FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with singleagent cetuximab. J Clin Oncol 25: 3712-8.
256. Zhang J., Liu X., Bell A., To R., Nath Baral T., Azizi A., Li J., Cass B., Durocher Y. (2009). Transient expression and purification of chimeric heavy chain antibodies. Protein Express Purif 65: 77-82.
257. Zhou Q., Shankara S., Roy A., Qiu H., Estes S., McVie-Wylie A., Culm-Merdek K., Park A., Pan C., Edmunds T. (2008). Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99: 652-65.